In this experiment, we examined a possible protective effect of encapsulated neurotrophic factor-secreting cell grafting for ischemic injury. We established a basic fibroblast growth factor (bFGF)-secreting cell line by genetic manipulation. We enveloped these cells into polymer capsules, which consist of a semipermeable membrane, and implanted them into the right striatum of rats. At 6 days after implantation, these rats received right middle cerebral artery occlusion (MCAO) using interluminal suture technique. At 24 h after MCAO, rats were sacrificed and their cerebral infarction volume was determined by 2,3,5-triphenyltetrazolium chloride (TTC) staining and image analysis. We found approximately 30% reduction in infarct volume in the encapsulated bFGF-secreting cell grafting groups vs. the encapsulated naive BHK cell grafting group or the without implantation group. We measured bFGF secretion from encapsulated bFGF-secreting cells using enzyme-linked immunosorbent assay (ELISA). The retrieved capsules continued to secrete bFGF. There was no significant difference of bFGF secretion between the capsules before and after transplantation. A large number of viable BHK-bFGF cells was observed within the full length of the retrieved capsule. These results indicate that encapsulated bFGF-secreting cell grafting exerts a protective effect on ischemic injury.
INTRODUCTION MATERIALS AND METHODS

Establishment of BHK-bFGF Cell Line Recently, the development of molecular biology tech-
We constructed rat bFGF expression vector, pABWniques has enabled the establishment of various types of Nrbfgf. bFGF cDNA was digested with EcoRI from cell lines that secrete neurotrophic factors. We consider pTB784, provided by Takeda Chemical Industries, Ltd. that the implantation of these newly generated cells is (16) . The fragment was introduced into the expression useful for delivery of neurotrophic factors into the brain.
vector pCAGGS, a gift from Dr. J Miyazaki, to be However, there are issues of immunological reaction driven by the CAG promoter, which is highly active in and tumorigenesis. To overcome these problems, techa wide range of cell types (21). The expression vector niques to envelop these cells into polymer capsules, was transfected into baby hamster kidney (BHK) cells which consist of semipermable membrane, have been (JCRB, Japan) using a cationic liposome (DOGS; Transdeveloped (2, 9, 10) . fectum reagent, Promega, USA)-mediated DNA delivery Basic fibroblast growth factor (bFGF) is one of the method. The transfected cells were selected in 200-800 most potent neurotrophic factors for the treatment of isµg/ml G418 (WAKO, Japan) for 4 weeks. The cell clone chemic injury (4, 11, 12, 17) . In this experiment, we estabsecreting the highest amount of bFGF was established lished a cell line that produces bFGF by genetic manipu-(clone 8). lation. We enveloped these cells into polymer capsules Encapsulation Procedure and implanted them into the right striatum of rats. At 6 days after implantation, these rats received right middle Sterile capsules made of polysulfon hollow fibers cerebral artery occlusion using interluminal suture techwere used in this experiment. These capsule exhibited nique in order to evaluate the protective efficacy of cross-sectional dimensions of 1.1 mm inner diameter and 7 mm in length. Confluent cultured BHK-bFGF or bFGF-secreting cell grafting in ischemic injury. naive BHK cells were harvested from the flask and sus-after retrieval using an enzyme-linked immunoabsorbent assay (ELISA) kit (WAKO). The capsules were rinsed pended in culture medium at a concentration of 5 × 10 7 cells/ml. Twenty microliters of this cellular suspension in HBSS and placed in 1 ml of fresh HBSS for 30 min. Supernatants were collected and stored at −80°C as sam-was loaded into capsules at the open end. After infusing of the cellar suspension, the access end was sealed with ples for bFGF ELISA. light-cured resin.
Statistical Analysis Transplantation and Permanent Middle Cerebral
Physiological parameters, bFGF, and ischemic area Artery Occlusion Procedure and volume were evaluated statistically using analysis Adult male Sprague-Dawley rats weighing 280-350 of variance (ANOVA) and post hoc Scheffe F-test. g were used in this experiment. They were maintained RESULTS at a room temperature of 24°C and were given food and water ad lib with a 12-h light-dark cycle.
Arterial blood gases and blood pressures were moni-The Animal Committee of the Okayama University tored in all animals during surgery, and there were no Medical School approved all experimental protocols and significant differences among the three groups. procedures. Encapsulated BHK-bFGF or naive BHK TTC staining showed that the infarct area of the cells were grafted into the right striatum of the rats 6 group that received encapsulated BHK-bFGF cell graftdays before middle cerebral artery occlusion (MCAO).
ing was significantly smaller than that of the control Briefly, rats were anesthetized with an IP injection of group ( Fig. 1 ). We found approximately 30% reduction pentobarbital (50 mg/kg) and positioned in a stereotaxic in infarct volume in the encapsulated bFGF-secreting frame. A burr hole of 2 mm diameter was made carecell grafting groups vs. the encapsulated naive BHK cell fully in their skull. The stereotaxic coordinates for capgrafting group or the without implantation group. sule implantation were 1 mm anterior to bregma, 3 mm
The cell-loaded devices were easily retrieved with litlateral to the sagittal suture, and 6 mm below the cortical tle or no host tissue adhering to the capsule wall. All surface.
capsules were removed intact and there was no evidence Permanent occlusion of middle cerebral artery was that any capsule broke either in situ or during the reinduced using the intraluminal suture technique with trieval procedure. The morphology of BHK-bFGF cells some modification (18, 19) . Rats were deeply anesthewithin a retrieved capsule is shown in Figure 2 . A large tized with an IP injection of pentobarbital (50 mg/kg).
number of viable BHK-bFGF cells was observed within All rats were monitored for arterial blood pressure durthe full length of the capsule. The amount of bFGF seing surgery and their blood gases were analyzed. The cretion from the capsule was approximately 20 ng per rats' body temperature was maintained at 37 ± 0.5°C day. There was no significant difference between the with an infrared heating pad. After surgery, the catheters bFGF secretion from the capsules before and after imwere removed and the animals were allowed to recover plantation. from anesthesia.
DISCUSSION Evaluation of Brain Injury After Permanent Middle
Recently, the protective or therapeutic efficacy of Cerebral Artery Occlusion several neurotrophic factors such as basic fibroblast At 24 h after MCAO, the animals were deeply anesgrowth factor (bFGF) (4, 11, 12) , glial cell line-derived thetized and then capsules were carefully retrieved for neurotrophic factor (GDNF) (1,14), brain-derived neurofurther evaluation. Immediately following capsule retrophic factor (BDNF) (24), nerve growth factor (NGF) trieval and while still under deep anesthesia, rats were (13) , and others for many types of injury of the brain transcardially perfused with 200 ml saline. Brains were has been reported. And recent development of molecular quickly removed and sectioned into six 2-mm coronal biology techniques enabled the establishment of various sections. These sections were stained with saline contypes of cell lines that secrete neurotrophic factors. We taining 2% 2,3,5-triphenyltetrazolium chloride (TTC) at have reported the effect of encapsulated cell grafting in 37°C for 30 min and were fixed in 10% buffered formaanimal models of Parkinson's disease (5, 9, 20) . In our lin. The six infarct areas between each adjoining slice previous study, we demonstrated that the co-grafting of were measured by NIH image software, and then the encapsulated NGF-secreting cells enhanced chromaffin infarct areas on each slice were summed and multiplied cell survival and behavioral recovery in hemiparkinsonby slice thickness to give the infarct volume.
ian rats (6) (7) (8) . The present experiment was designed to bFGF ELISA evaluate the application of encapsulated neurotrophic factor-producing cell grafting for ischemic injury. We measured the amount of bFGF secretion from encapsulated BHK-bFGF cells before implantation and bFGF is an 18-kDa protein with potent tropic effect duction of infarct volume in the animals receiving encapsulated BHK-bFGF cell grafting. The amount of bFGF secreted from the capsules was between 15 and 30 ng per day. bFGF at 45 µg/kg/h or 135 µg/kg has been used for intravenous administration and 1.2 µg of bFGF has been used for intracisternal administration in the previously reported studies. Although the total amount of bFGF delivered from the capsules was approximately 100 ng per animal in the present study, there was a significant decrease in infarct volume. In in vitro studies, bFGF exerted potent neurotrophic and neuroprotective effects at 1-10 ng/ml (16, 23) . These results suggest that continuous and direct administration of a low dose of bFGF enabled it to exert neuroprotective effects in acute ischemic injury. We demonstrated that the encapsulated bFGF-producing cell grafting protects ischemic injury in the present study. Studies are currently under way in our laboratory to evaluate the efficacy for delayed neuronal death and for long-term functional recovery, and whether encapsulated cell grafting is effective even if performed after induction of ischemia. of bFGF for ischemic injury. Intraperitonial administra-REFFERENCES tion of bFGF reduced the size of focal cerebral infarcts
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